Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage
biopharmaceutical company whose mission is to focus on unmet needs
and apply proven science and new technology to revolutionize
treatment for patients, starting with eye care, today announced the
appointment of Rosemary A. Crane to its Board of Directors. Ms.
Crane will serve as the Chair of the newly created Science and
Technology Committee, focused on external and internal innovation
and pipeline opportunities. Ms. Crane has more than 30 years of
extensive experience in the pharmaceutical industry, including
executive leadership, board service, innovation, business
development, operations, and global commercialization expertise.
“We are delighted to welcome Rose to our Board of Directors at
such an important and exciting time for Tarsus,” said Michael
Ackermann, Ph.D., Chairman of Tarsus’ Board of Directors. “Her
wealth of relevant industry experience will add tremendous value to
our Board as the company navigates many significant near-term and
future milestones.”
Ms. Crane brings significant executive leadership experience and
operating expertise to the Tarsus Board, having previously served
as President and Chief Executive Officer of both MELA Sciences,
Inc. (now Strata Skin Sciences) and Epocrates, Inc., as well as
Partner and Head of Commercialization at Appletree Partners. Prior
to that, Ms. Crane held several senior executive positions at
Johnson & Johnson, including Group Chairman, OTC &
Nutritional Group, leading the largest worldwide OTC company.
Earlier in her career, she spent 20 years at Bristol Myers Squibb,
completing her tenure as President, U.S. Primary Care.
“Rose’s expertise in innovation, commercialization, and
dedication to the industry are invaluable as we look toward future
pipeline products and move closer to the potential
commercialization of TP-03, our lead product for the treatment of
Demodex blepharitis,” said Bobak Azamian, M.D., Ph.D., President
and Chief Executive Officer of Tarsus.
Ms. Crane currently sits on the boards of Teva Pharmaceuticals
Industries Ltd. and Catalent, Inc., as well as acts as a director
of the Hackensack Meridian Health Center for Discovery and
Innovation. Previously, she served on the boards of several
pharmaceutical and life sciences companies, including Edge
Therapeutics, Inc., Unilife Corporation, Cipher Pharmaceuticals
Inc., Targanta Therapeutics Corp., and Zealand Pharma A/S. Ms.
Crane received a B.A. in communications and English from the State
University of New York at Oswego and an MBA from Kent State
University.
“I am honored to join the Tarsus Board of Directors during this
pivotal moment in the company’s growth,” said Ms. Crane. “I look
forward to being part of Tarsus’ exciting future as the company
prepares for the potential launch of TP-03, and as it looks to
develop additional innovative therapeutics to address important
unmet patient needs.”
About Tarsus Pharmaceuticals, Inc.Tarsus
Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical
company that applies proven science and new technology to
revolutionize treatment for patients, starting with eye care. It is
advancing its pipeline to address several diseases with high unmet
need across a range of therapeutic categories, including eye care,
dermatology, and infectious disease prevention. The company is
studying two investigational medicines in clinical trials. Its lead
product candidate, TP-03, is a novel therapeutic being studied in a
second Phase 3 pivotal trial for the treatment of Demodex
blepharitis. TP-03 is also being developed for the treatment of
Meibomian Gland Disease. Tarsus is developing TP-05, an oral,
non-vaccine therapeutic for the prevention of Lyme disease, which
is currently being studied in a Phase 1 clinical trial.
Forward Looking Statements Statements in this
press release about future expectations, plans and prospects, as
well as any other statements regarding matters that are not
historical facts, may constitute “forward-looking statements.”
These statements include statements regarding Tarsus’ plans for and
the anticipated benefits of its product candidates, including
TP-03, the benefits and value added by the new director, the
timing, objectives and results of the clinical trials and
anticipated regulatory and development milestones, including the
potential commercialization of the Company’s products, and the
quotations of Tarsus’ management and board members. The words,
without limitation, “believe,” “contemplate,” “continue,” “could,”
“estimate,” “expect,” “intend,” “may,” “might,” “plan,”
“potential,” “predict,” “project,” “should,” “target,” “will,” or
“would,” or the negative of these terms or other similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these or
similar identifying words. Actual results may differ materially
from those indicated by such forward-looking statements as a result
of various important factors and are detailed from time to time in
the reports Tarsus files with the Securities and Exchange
Commission, including Tarsus’ Form 10-K for the year ended December
31, 2020 filed with the SEC on March 31, 2021 and Form 10-Q for the
quarter ended June 30, 2021 filed with the SEC on August 5, 2021,
which Tarsus incorporates by reference into this press release and
copies of which are posted on its website and are available from
Tarsus without charge. However, new risk factors and uncertainties
may emerge from time to time, and it is not possible to predict all
risk factors and uncertainties. Accordingly, readers are cautioned
not to place undue reliance on these forward-looking statements.
Any forward-looking statements contained in this press release are
based on the current expectations of Tarsus’ management team and
speak only as of the date hereof, and Tarsus specifically disclaims
any obligation to update any forward-looking statement, whether as
a result of new information, future events or otherwise.
Contacts: Media Contact:SuJin Oh Shop PR(917)
841-5213sujin@shop-pr.com
Investor Contact:Patti BankWestwicke Partners, an ICR
company(415) 513-1284IR@tarsusrx.com
Tarsus Pharmaceuticals (NASDAQ:TARS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tarsus Pharmaceuticals (NASDAQ:TARS)
Historical Stock Chart
From Apr 2023 to Apr 2024